New study reveals key factors in 90-Day survival for advanced cancer patients after ER
NCT ID NCT07167095
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study reviewed medical records of 1,250 advanced cancer patients who visited the emergency department. Researchers looked at factors like age, tumor type, and blood test results to see which patients were at higher risk of dying within 90 days. The goal is to help doctors better triage and refer patients to supportive care after an ER visit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify which advanced cancer patients need extra support or palliative care after an ER visit, potentially improving their quality of life.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly change patient care. The findings may not apply to other hospitals or countries.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ankara Etlik City Hospital
Ankara, Yenimahalle, 06210, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could starting feeds sooner shield preterm babies from infection?
- A lifeline for cancer caregivers: can simple phone support reduce their stress?
- Could a breathing exercise and music tame cancer treatment fatigue?
- A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
- Can a single antibiotic dose cut child mortality in niger?
- Can a new infusion drug shrink Hard-to-Treat tumors?